Seoulin Bioscience Company Limited operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Seoulin Bioscience Company Limited with three other
companies in this sector in KOREA (SOUTH) :
Medipost Co Ltd
sales of 45.81 billion Korean Won [US$37.20 million]
of which 49%
was Umbilical Cord Blood),
(36.29 billion Korean Won [US$29.47 million]
of which 50%
was DNA/RNA molecular diagnostic kits), and
Legochem Biosciences Inc
(57.50 billion Korean Won [US$46.69 million]
of which 55%
was New Drugs R & D).
During the year ended December of 2019, sales at
Seoulin Bioscience Company Limited were 54.41 billion Korean Won (US$44.18 million).
increase of 9.1%
versus 2018, when the company's sales were 49.88 billion Korean Won .
Sales of Biotechnology saw an increase
10.2% in 2019, from
45.83 billion Korean Won to 50.52 billion Korean Won .
Not all segments of Seoulin Bioscience Company Limited experienced an increase in sales in 2019:
sales of Healthcare fell 3.7% to 3.89 billion Korean Won .